BidaskClub lowered shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) from a buy rating to a hold rating in a report released on Friday morning.

Several other analysts have also commented on the company. Morgan Stanley set a $168.00 target price on Jazz Pharmaceuticals and gave the stock a hold rating in a report on Wednesday, November 28th. Mizuho dropped their target price on Jazz Pharmaceuticals to $157.00 and set a neutral rating on the stock in a report on Tuesday, November 20th. HC Wainwright reaffirmed a hold rating and set a $161.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, November 14th. ValuEngine raised Jazz Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, November 13th. Finally, Zacks Investment Research reaffirmed a hold rating on shares of Jazz Pharmaceuticals in a report on Tuesday, November 13th. Six equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. The stock has an average rating of Buy and an average price target of $189.76.

Shares of NASDAQ:JAZZ opened at $141.17 on Friday. Jazz Pharmaceuticals has a 52-week low of $130.15 and a 52-week high of $184.00. The stock has a market capitalization of $8.66 billion, a PE ratio of 14.77, a PEG ratio of 0.86 and a beta of 0.94. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.29 and a quick ratio of 4.16.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.32 by $0.26. The firm had revenue of $469.37 million during the quarter, compared to analysts’ expectations of $482.64 million. Jazz Pharmaceuticals had a return on equity of 24.92% and a net margin of 28.09%. The company’s revenue for the quarter was up 14.0% compared to the same quarter last year. During the same period last year, the business posted $3.22 earnings per share. As a group, equities analysts predict that Jazz Pharmaceuticals will post 11.6 earnings per share for the current fiscal year.

In other Jazz Pharmaceuticals news, Director Seamus Mulligan acquired 50,000 shares of the company’s stock in a transaction on Thursday, November 15th. The shares were bought at an average cost of $144.56 per share, with a total value of $7,228,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, September 14th. The stock was sold at an average price of $165.20, for a total value of $33,040.00. Following the completion of the sale, the executive vice president now directly owns 25,372 shares in the company, valued at $4,191,454.40. The disclosure for this sale can be found here. Over the last three months, insiders sold 6,600 shares of company stock worth $1,063,472. 3.90% of the stock is owned by corporate insiders.

Large investors have recently modified their holdings of the company. Russell Investments Group Ltd. boosted its stake in shares of Jazz Pharmaceuticals by 113.7% in the second quarter. Russell Investments Group Ltd. now owns 68,430 shares of the specialty pharmaceutical company’s stock worth $11,798,000 after acquiring an additional 36,415 shares during the last quarter. Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of Jazz Pharmaceuticals in the third quarter worth approximately $8,868,000. BlackRock Inc. boosted its stake in shares of Jazz Pharmaceuticals by 2.7% in the third quarter. BlackRock Inc. now owns 4,490,714 shares of the specialty pharmaceutical company’s stock worth $755,024,000 after acquiring an additional 118,634 shares during the last quarter. Legal & General Group Plc boosted its stake in shares of Jazz Pharmaceuticals by 1.8% in the second quarter. Legal & General Group Plc now owns 241,295 shares of the specialty pharmaceutical company’s stock worth $41,575,000 after acquiring an additional 4,268 shares during the last quarter. Finally, Kepos Capital LP acquired a new stake in shares of Jazz Pharmaceuticals in the third quarter worth approximately $6,324,000. 91.53% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Further Reading: Stock Symbols and CUSIP Explained

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.